COEP
NASDAQ · Biotechnology
Coeptis Therapeutics Holding
$9.84
-1.46 (-12.92%)
Financial Highlights (FY 2026)
Revenue
2.06M
Net Income
-17,995,573
Gross Margin
86.7%
Profit Margin
-874.3%
Rev Growth
—
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 86.7% | 41.5% | 41.5% | 41.5% |
| Operating Margin | -945.3% | -18.5% | -17.7% | -18.7% |
| Profit Margin | -874.3% | -23.2% | -17.3% | -20.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.06M | 8.74M | 7.84M | 7.34M |
| Gross Profit | 1.79M | 3.63M | 3.26M | 3.05M |
| Operating Income | -19,458,212 | -1,614,893 | -1,391,919 | -1,371,436 |
| Net Income | -17,995,573 | -2,031,310 | -1,359,886 | -1,470,733 |
| Gross Margin | 86.7% | 41.5% | 41.5% | 41.5% |
| Operating Margin | -945.3% | -18.5% | -17.7% | -18.7% |
| Profit Margin | -874.3% | -23.2% | -17.3% | -20.0% |
| Rev Growth | — | +14.6% | -0.2% | +5.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 922.0K | 13.09M | 13.18M | 12.69M |
| Total Equity | 50.11M | 46.40M | 52.11M | 53.17M |
| D/E Ratio | 0.02 | 0.28 | 0.25 | 0.24 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -18,585,812 | -2,389,064 | -2,398,436 | -1,921,173 |
| Free Cash Flow | — | -1,186,852 | -1,098,506 | -895,782 |